Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Ing SW, Orchard TS, Lu B, LaMonte MJ, Barbour KE, Cauley JA, Jackson RD. TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association. J Clin Endocrinol Metab. 2015 Sep; 100(9):3380-7.
-
Alimchandani M, Wang ZF, Miettinen M. CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases. Appl Immunohistochem Mol Morphol. 2014 May-Jun; 22(5):358-62.
-
Bruminhent J, Lynch TK, Gefen J, Santoro J. Listeria monocytogenes cholecystitis: a possible new syndrome. Am J Med Sci. 2013 May; 345(5):414-7.
-
Pai S, Rosenstein ED, Kramer N. Etanercept therapy for psoriatic arthritis in the presence of recurrent non-Hodgkin lymphoma. J Clin Rheumatol. 2012 Sep; 18(6):301-3.
-
Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, Sculpher M. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford). 2011 Sep; 50 Suppl 4:iv39-iv47.
-
Liu S, Yin T, Wei X, Yi W, Qu Y, Liu Y, Wang R, Lian K, Xia C, Pei H, Sun L, Ma Y, Lau WB, Gao E, Koch WJ, Wang H, Tao L. Downregulation of adiponectin induced by tumor necrosis factor a is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med. 2011 Aug; 39(8):1935-43.
-
Chang MB, Sri JC, Driscoll M, Gaspari AA. Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers. J Drugs Dermatol. 2011 Aug; 10(8):914-6.
-
Zhou SY, Shu C, Korth-Bradley J, Raible D, Palmisano M, Wadjula J, Fatenejad S, Bjornsson T. Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol. 2011 Jun; 51(6):864-75.
-
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010 Mar 01; 171(5):571-82.
-
Chapman P, Cranmer L, Dixon WG, Hyrich KL, Patterson JR, Symmons DP, Toporcer M, Mastrangelo MJ. The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol. 2010 Feb; 37(1):11-9.